The pharmacological point of view of resistance to therapy in tumors

Cancer Treatment Reviews

Volumn 40, Issue 8, 2014, Pages 909-916

  Damia, Giovanna ^a   Garattini, Silvio ^a  

^a MARIO NEGRI INSTITUTE FOR PHARMACOLOGICAL RESEARCH   (Italy)

Author keywords

Drug distribution; Resistance; Tumor heterogeneity

Indexed keywords

ABC TRANSPORTER; ANTINEOPLASTIC AGENT; BREAST CANCER RESISTANCE PROTEIN; MULTIDRUG RESISTANCE ASSOCIATED PROTEIN 1; MULTIDRUG RESISTANCE PROTEIN 1;

CANCER CELL POPULATION HETEROGENEITY; CANCER CHEMOTHERAPY; DRUG ABSORPTION; DRUG CONCENTRATION; DRUG DISTRIBUTION; DRUG ELIMINATION; DRUG MECHANISM; DRUG METABOLISM; DRUG PENETRATION; DRUG SENSITIVITY; DRUG TRANSPORT; DRUG USE; GENETIC HETEROGENEITY; HUMAN; META ANALYSIS (TOPIC); NEOPLASM; NONHUMAN; ONCOLOGICAL PARAMETERS; PHASE 1 CLINICAL TRIAL (TOPIC); REVIEW; SPATIOTEMPORAL ANALYSIS; TIME TO TREATMENT; TREATMENT RESPONSE; TUMOR CELL; TUMOR GROWTH; TUMOR MICROENVIRONMENT; TUMOR RESISTANCE; TUMOR VASCULARIZATION;

DRUG DISTRIBUTION; RESISTANCE; TUMOR HETEROGENEITY;

ANIMALS; ANTINEOPLASTIC AGENTS; DRUG RESISTANCE, NEOPLASM; HUMANS; NEOPLASMS;

EID: 84904818154     PISSN: 03057372     EISSN: 15321967     Source Type: Journal    
DOI: 10.1016/j.ctrv.2014.05.008     Document Type: Review

References (117)

1. Holohan C., Van Schaeybroeck S., Longley D.B., Johnston P.G. Cancer drug resistance: an evolving paradigm. Nat Rev Cancer 2013, 13:714-726.
2. Crockford A., Jamal-Hanjani M., Hicks J., Swanton C. Implications of intratumour heterogeneity for treatment stratification. J Pathol 2014, 232:264-273.
3. Weng L., Zhang L., Peng Y., Huang R.S. Pharmacogenetics and pharmacogenomics: a bridge to individualized cancer therapy. Pharmacogenomics 2013, 14:315-324.
4. Wurz G.T., Degregorio M.W. Activating adaptive cellular mechanisms of resistance following sub-lethal cytotoxic chemotherapy: implications for diagnostic microdosing. Int J Cancer 2014.
5. Chang B.D., Broude E.V., Dokmanovic M., Zhu H., Ruth A., Xuan Y., et al. A senescence-like phenotype distinguishes tumor cells that undergo terminal proliferation arrest after exposure to anticancer agents. Cancer Res 1999, 59:3761-3767.
6. Elmore L.W., Di X., Dumur C., Holt S.E., Gewirtz D.A. Evasion of a single-step, chemotherapy-induced senescence in breast cancer cells: implications for treatment response. Clin Cancer Res 2005, 11:2637-2643.
7. Gordon R.R., Nelson P.S. Cellular senescence and cancer chemotherapy resistance. Drug Resist Updat 2012, 15:123-131.
8. Lappin G. Microdosing: current and the future. Bioanalysis 2010, 2:509-517.
9. Minchinton A.I., Tannock I.F. Drug penetration in solid tumours. Nat Rev Cancer 2006, 6:583-592.
10. Jain R.K. Delivery of molecular medicine to solid tumors. Science 1996, 271:1079-1080.
11. Marcucci F., Corti A. How to improve exposure of tumor cells to drugs: promoter drugs increase tumor uptake and penetration of effector drugs. Adv Drug Deliv Rev 2012, 64:53-68.
12. Carmeliet P., Jain R.K. Angiogenesis in cancer and other diseases. Nature 2000, 407:249-257.
13. Heldin C.H., Rubin K., Pietras K., Ostman A. High interstitial fluid pressure - an obstacle in cancer therapy. Nat Rev Cancer 2004, 4:806-813.
14. Netti P.A., Berk D.A., Swartz M.A., Grodzinsky A.J., Jain R.K. Role of extracellular matrix assembly in interstitial transport in solid tumors. Cancer Res 2000, 60:2497-2503.
15. Harris A.L. Hypoxia-a key regulatory factor in tumour growth. Nat Rev Cancer 2002, 2:38-47.
16. Broggini M., Italia C., Colombo T., Marmonti L., Donelli M.G. Activity and distribution of iv and oral 4-demethoxydaunorubicin in murine experimental tumors. Cancer Treat Rep 1984, 68:739-747.
17. Donelli M.G., D'Incalci M., Garattini S. Pharmacokinetic studies of anticancer drugs in tumor-bearing animals. Cancer Treat Rep 1984, 68:381-400.
18. Rossi C., Gasparini G., Canobbio L., Galligioni E., Volpe R., Candiani E., et al. Doxorubicin distribution in human breast cancer. Cancer Treat Rep 1987, 71:1221-1226.
19. Stallard S., Morrison J.G., George W.D., Kaye S.B. Distribution of doxorubicin to normal breast and tumour tissue in patients undergoing mastectomy. Cancer Chemother Pharmacol 1990, 25:286-290.
20. Koshiba H., Hosokawa K., Mori T., Kubo A., Watanabe A., Honjo H. Intravenous paclitaxel is specifically retained in human gynecologic carcinoma tissues in vivo. Int J Gynecol Cancer 2009, 19:484-488.
21. Amiri-Kordestani L., Basseville A., Kurdziel K., Fojo A.T., Bates S.E. Targeting MDR in breast and lung cancer: discriminating its potential importance from the failure of drug resistance reversal studies. Drug Resist Updat 2012, 15:50-61.
22. Lankelma J., Dekker H., Luque F.R., Luykx S., Hoekman K., van der Valk P., et al. Doxorubicin gradients in human breast cancer. Clin Cancer Res 1999, 5:1703-1707.
23. Primeau A.J., Rendon A., Hedley D., Lilge L., Tannock I.F. The distribution of the anticancer drug doxorubicin in relation to blood vessels in solid tumors. Clin Cancer Res 2005, 11:8782-8788.
24. Patel K.J., Tredan O., Tannock I.F. Distribution of the anticancer drugs doxorubicin, mitoxantrone and topotecan in tumors and normal tissues. Cancer Chemother Pharmacol 2013, 72:127-138.
25. Morosi L., Zucchetti M., D'Incalci M., Davoli E. Imaging mass spectrometry: challenges in visualization of drug distribution in solid tumors. Curr Opin Pharmacol 2013, 13:807-812.
26. Morosi L., Spinelli P., Zucchetti M., Pretto F., Carra A., D'Incalci M., et al. Determination of paclitaxel distribution in solid tumors by nano-particle assisted laser desorption ionization mass spectrometry imaging. PLoS One 2013, 8:e72532.
27. Erkan M., Reiser-Erkan C., Michalski C.W., Kleeff J. Tumor microenvironment and progression of pancreatic cancer. Exp Oncol 2010, 32:128-131.
28. Neesse A., Michl P., Frese K.K., Feig C., Cook N., Jacobetz M.A., et al. Stromal biology and therapy in pancreatic cancer. Gut 2011, 60:861-868.
29. Provenzano P.P., Hingorani S.R. Hyaluronan, fluid pressure, and stromal resistance in pancreas cancer. Br J Cancer 2013, 108:1-8.
30. Provenzano P.P., Cuevas C., Chang A.E., Goel V.K., Von Hoff D.D., Hingorani S.R. Enzymatic targeting of the stroma ablates physical barriers to treatment of pancreatic ductal adenocarcinoma. Cancer Cell 2012, 21:418-429.
31. Sultana S., Khan M.R., Kumar M., Kumar S., Ali M. Nanoparticles-mediated drug delivery approaches for cancer targeting: a review. J Drug Target 2013, 21:107-125.
32. Li L., Sun J., He Z. Deep penetration of nanoparticulate drug delivery systems into tumors: challenges and solutions. Curr Med Chem 2013, 20:2881-2891.
33. Kirtane A.R., Kalscheuer S.M., Panyam J. Exploiting nanotechnology to overcome tumor drug resistance: challenges and opportunities. Adv Drug Deliv Rev 2013, 65:1731-1747.
34. Holgado M.A., Martin-Banderas L., Alvarez-Fuentes J., Fernandez-Arevalo M., Arias J.L. Drug targeting to cancer by nanoparticles surface functionalized with special biomolecules. Curr Med Chem 2012, 19:3188-3195.
35. Szakacs G., Paterson J.K., Ludwig J.A., Booth-Genthe C., Gottesman M.M. Targeting multidrug resistance in cancer. Nat Rev Drug Discov 2006, 5:219-234.
36. Dean M., Rzhetsky A., Allikmets R. The human ATP-binding cassette (ABC) transporter superfamily. Genome Res 2001, 11:1156-1166.
37. Gottesman M.M., Fojo T., Bates S.E. Multidrug resistance in cancer: role of ATP-dependent transporters. Nat Rev Cancer 2002, 2:48-58.
38. Robey R.W., Polgar O., Deeken J., To K.W., Bates S.E. ABCG2: determining its relevance in clinical drug resistance. Cancer Metastasis Rev 2007, 26:39-57.
39. Chen K.G., Sikic B.I. Molecular pathways: regulation and therapeutic implications of multidrug resistance. Clin Cancer Res 2012, 18:1863-1869.
40. Thomas H., Coley H.M. Overcoming multidrug resistance in cancer: an update on the clinical strategy of inhibiting p-glycoprotein. Cancer Control 2003, 10:159-165.
41. Clarke R., Leonessa F., Trock B. Multidrug resistance/P-glycoprotein and breast cancer: review and meta-analysis. Semin Oncol 2005, 32:S9-S15.
42. Xia C.Q., Smith P.G. Drug efflux transporters and multidrug resistance in acute leukemia: therapeutic impact and novel approaches to mediation. Mol Pharmacol 2012, 82:1008-1021.
43. Colone M., Calcabrini A., Toccacieli L., Bozzuto G., Stringaro A., Gentile M., et al. The multidrug transporter P-glycoprotein: a mediator of melanoma invasion?. J Invest Dermatol 2008, 128:957-971.
44. Mignogna C., Staibano S., Altieri V., De Rosa G., Pannone G., Santoro A., et al. Prognostic significance of multidrug-resistance protein (MDR-1) in renal clear cell carcinomas: a five year follow-up analysis. BMC Cancer 2006, 6:293.
45. Triller N., Korosec P., Kern I., Kosnik M., Debeljak A. Multidrug resistance in small cell lung cancer: expression of P-glycoprotein, multidrug resistance protein 1 and lung resistance protein in chemo-naive patients and in relapsed disease. Lung Cancer 2006, 54:235-240.
46. Doyle L.A., Yang W., Abruzzo L.V., Krogmann T., Gao Y., Rishi A.K., et al. A multidrug resistance transporter from human MCF-7 breast cancer cells. Proc Natl Acad Sci USA 1998, 95:15665-15670.
47. Ricci F., Bernasconi S., Perego P., Ganzinelli M., Russo G., Bono F., et al. Ovarian carcinoma tumor-initiating cells have a mesenchymal phenotype. Cell Cycle 2012, 11:1966-1976.
48. Tirino V., Desiderio V., Paino F., De Rosa A., Papaccio F., La Noce M., et al. Cancer stem cells in solid tumors: an overview and new approaches for their isolation and characterization. FASEB J 2013, 27:13-24.
49. Pusztai L., Wagner P., Ibrahim N., Rivera E., Theriault R., Booser D., et al. Phase II study of tariquidar, a selective P-glycoprotein inhibitor, in patients with chemotherapy-resistant, advanced breast carcinoma. Cancer 2005, 104:682-691.
50. Ruff P., Vorobiof D.A., Jordaan J.P., Demetriou G.S., Moodley S.D., Nosworthy A.L., et al. A randomized, placebo-controlled, double-blind Phase 2 study of docetaxel compared to docetaxel plus zosuquidar (LY335979) in women with metastatic or locally recurrent breast cancer who have received one prior chemotherapy regimen. Cancer Chemother Pharmacol 2009, 64:763-768.
51. Abraham J., Edgerly M., Wilson R., Chen C., Rutt A., Bakke S., et al. A Phase I study of the P-glycoprotein antagonist tariquidar in combination with vinorelbine. Clin Cancer Res 2009, 15:3574-3582.
52. Damia G., D'Incalci M. Targeting DNA repair as a promising approach in cancer therapy. Eur J Cancer 2007, 43:1791-1801.
53. Damia G., D'Incalci M. Genetic instability influences drug response in cancer cells. Curr Drug Targets 2010, 11:1317-1324.
54. Rochat B. Importance of influx and efflux systems and xenobiotic metabolizing enzymes in intratumoral disposition of anticancer agents. Curr Cancer Drug Targets 2009, 9:652-674.
55. Nowell P.C. The clonal evolution of tumor cell populations. Science 1976, 194:23-28.
56. Murugaesu N., Chew S.K., Swanton C. Adapting clinical paradigms to the challenges of cancer clonal evolution. Am J Pathol 2013, 182:1962-1971.
57. Greaves M., Maley C.C. Clonal evolution in cancer. Nature 2012, 481:306-313.
58. Burrell R.A., McGranahan N., Bartek J., Swanton C. The causes and consequences of genetic heterogeneity in cancer evolution. Nature 2013, 501:338-345.
59. Ashworth A., Lord C.J., Reis-Filho J.S. Genetic interactions in cancer progression and treatment. Cell 2011, 145:30-38.
60. Meacham C.E., Morrison S.J. Tumour heterogeneity and cancer cell plasticity. Nature 2013, 501:328-337.
61. Bonnet D., Dick J.E. Human acute myeloid leukemia is organized as a hierarchy that originates from a primitive hematopoietic cell. Nat Med 1997, 3:730-737.
62. Wang J.C., Lapidot T., Cashman J.D., Doedens M., Addy L., Sutherland D.R., et al. High level engraftment of NOD/SCID mice by primitive normal and leukemic hematopoietic cells from patients with chronic myeloid leukemia in chronic phase. Blood 1998, 91:2406-2414.
63. Al-Hajj M., Wicha M.S., Benito-Hernandez A., Morrison S.J., Clarke M.F. Prospective identification of tumorigenic breast cancer cells. Proc Natl Acad Sci USA 2003, 100:3983-3988.
64. Singh S.K., Hawkins C., Clarke I.D., Squire J.A., Bayani J., Hide T., et al. Identification of human brain tumour initiating cells. Nature 2004, 432:396-401.
65. Ricci-Vitiani L., Lombardi D.G., Pilozzi E., Biffoni M., Todaro M., Peschle C., et al. Identification and expansion of human colon-cancer-initiating cells. Nature 2007, 445:111-115.
66. Li C., Heidt D.G., Dalerba P., Burant C.F., Zhang L., Adsay V., et al. Identification of pancreatic cancer stem cells. Cancer Res 2007, 67:1030-1037.
67. Stewart J.M., Shaw P.A., Gedye C., Bernardini M.Q., Neel B.G., Ailles L.E. Phenotypic heterogeneity and instability of human ovarian tumor-initiating cells. Proc Natl Acad Sci USA 2011, 108:6468-6473.
68. Quintana E., Shackleton M., Foster H.R., Fullen D.R., Sabel M.S., Johnson T.M., et al. Phenotypic heterogeneity among tumorigenic melanoma cells from patients that is reversible and not hierarchically organized. Cancer Cell 2010, 18:510-523.
69. Quintana E., Shackleton M., Sabel M.S., Fullen D.R., Johnson T.M., Morrison S.J. Efficient tumour formation by single human melanoma cells. Nature 2008, 456:593-598.
70. Komaki K., Sano N., Tangoku A. Problems in histological grading of malignancy and its clinical significance in patients with operable breast cancer. Breast cancer 2006, 13:249-253.
71. Baldus S.E., Schaefer K.L., Engers R., Hartleb D., Stoecklein N.H., Gabbert H.E. Prevalence and heterogeneity of KRAS, BRAF, and PIK3CA mutations in primary colorectal adenocarcinomas and their corresponding metastases. Clin Cancer Res 2010, 16:790-799.
72. Davila E., Amazon K. The Clinical Importance of the Heterogeneity of HER2 neu. Case Rep Oncol 2010, 3:268-271.
73. Furuya T., Uchiyama T., Murakami T., Adachi A., Kawauchi S., Oga A., et al. Relationship between chromosomal instability and intratumoral regional DNA ploidy heterogeneity in primary gastric cancers. Clin Cancer Res 2000, 6:2815-2820.
74. Teixeira M.R., Pandis N., Bardi G., Andersen J.A., Heim S. Karyotypic comparisons of multiple tumorous and macroscopically normal surrounding tissue samples from patients with breast cancer. Cancer Res 1996, 56:855-859.
75. Ulahannan D., Kovac M.B., Mulholland P.J., Cazier J.B., Tomlinson I. Technical and implementation issues in using next-generation sequencing of cancers in clinical practice. Br J Cancer 2013, 109:827-835.
76. Navin N., Krasnitz A., Rodgers L., Cook K., Meth J., Kendall J., et al. Inferring tumor progression from genomic heterogeneity. Genome Res 2010, 20:68-80.
77. Nickel G.C., Barnholtz-Sloan J., Gould M.P., McMahon S., Cohen A., Adams M.D., et al. Characterizing mutational heterogeneity in a glioblastoma patient with double recurrence. PLoS One 2012, 7:e35262.
78. Szerlip N.J., Pedraza A., Chakravarty D., Azim M., McGuire J., Fang Y., et al. Intratumoral heterogeneity of receptor tyrosine kinases EGFR and PDGFRA amplification in glioblastoma defines subpopulations with distinct growth factor response. Proc Natl Acad Sci USA 2012, 109:3041-3046.
79. Larzabal L., El-Nikhely N., Redrado M., Seeger W., Savai R., Calvo A. Differential effects of drugs targeting cancer stem cell (CSC) and non-CSC populations on lung primary tumors and metastasis. PLoS One 2013, 8:e79798.
80. Zhao Y., Bao Q., Schwarz B., Zhao L., Mysliwietz J., Ellwart J., et al. Stem celllike side populations in esophageal cancer: a source of chemotherapy resistance and metastases. Stem Cells Dev 2013.
81. Huntly B.J., Gilliland D.G. Leukaemia stem cells and the evolution of cancer-stem-cell research. Nat Rev Cancer 2005, 5:311-321.
82. Kreso A., O'Brien C.A., van Galen P., Gan O.I., Notta F., Brown A.M., et al. Variable clonal repopulation dynamics influence chemotherapy response in colorectal cancer. Science 2013, 339:543-548.
83. Vidal S.J., Rodriguez-Bravo V., Galsky M., Cordon-Cardo C., Domingo-Domenech J. Targeting cancer stem cells to suppress acquired chemotherapy resistance. Oncogene 2013.
84. Tamura K., Aoyagi M., Ando N., Ogishima T., Wakimoto H., Yamamoto M., et al. Expansion of CD133-positive glioma cells in recurrent de novo glioblastomas after radiotherapy and chemotherapy. J Neurosurg 2013, 119:1145-1155.
85. Silva I.A., Bai S., McLean K., Yang K., Griffith K., Thomas D., et al. Aldehyde dehydrogenase in combination with CD133 defines angiogenic ovarian cancer stem cells that portend poor patient survival. Cancer Res 2011, 71:3991-4001.
86. Jiang X., Forrest D., Nicolini F., Turhan A., Guilhot J., Yip C., et al. Properties of CD34+CML stem/progenitor cells that correlate with different clinical responses to imatinib mesylate. Blood 2010, 116:2112-2121.
87. Pfeifer H., Wassmann B., Pavlova A., Wunderle L., Oldenburg J., Binckebanck A., et al. Kinase domain mutations of BCR-ABL frequently precede imatinib-based therapy and give rise to relapse in patients with de novo Philadelphia-positive acute lymphoblastic leukemia (Ph+ ALL). Blood 2007, 110:727-734.
88. Iqbal Z., Aleem A., Iqbal M., Naqvi M.I., Gill A., Taj A.S., et al. Sensitive detection of pre-existing BCR-ABL kinase domain mutations in CD34+ cells of newly diagnosed chronic-phase chronic myeloid leukemia patients is associated with imatinib resistance: implications in the post-imatinib era. PLoS One 2013, 8:e55717.
89. Keats J.J., Chesi M., Egan J.B., Garbitt V.M., Palmer S.E., Braggio E., et al. Clonal competition with alternating dominance in multiple myeloma. Blood 2012, 120:1067-1076.
90. Pfeifer H., Lange T., Wystub S., Wassmann B., Maier J., Binckebanck A., et al. Prevalence and dynamics of bcr-abl kinase domain mutations during imatinib treatment differ in patients with newly diagnosed and recurrent bcr-abl positive acute lymphoblastic leukemia. Leukemia 2012, 26:1475-1481.
91. Chomel J.C., Turhan A.G. Chronic myeloid leukemia stem cells in the era of targeted therapies: resistance, persistence and long-term dormancy. Oncotarget 2011, 2:713-727.
92. Sequist L.V., Waltman B.A., Dias-Santagata D., Digumarthy S., Turke A.B., Fidias P., et al. Genotypic and histological evolution of lung cancers acquiring resistance to EGFR inhibitors. Sci Transl Med 2011, 3:75ra26.
93. Su K.Y., Chen H.Y., Li K.C., Kuo M.L., Yang J.C., Chan W.K., et al. Pretreatment epidermal growth factor receptor (EGFR) T790M mutation predicts shorter EGFR tyrosine kinase inhibitor response duration in patients with non-small-cell lung cancer. J Clin Oncol 2012, 30:433-440.
94. Turke A.B., Zejnullahu K., Wu Y.L., Song Y., Dias-Santagata D., Lifshits E., et al. Preexistence and clonal selection of MET amplification in EGFR mutant NSCLC. Cancer Cell 2010, 17:77-88.
95. Amir E., Clemons M., Purdie C.A., Miller N., Quinlan P., Geddie W., et al. Tissue confirmation of disease recurrence in breast cancer patients: pooled analysis of multi-centre, multi-disciplinary prospective studies. Cancer Treat Rev 2012, 38:708-714.
96. Dupont Jensen J., Laenkholm A.V., Knoop A., Ewertz M., Bandaru R., Liu W., et al. PIK3CA mutations may be discordant between primary and corresponding metastatic disease in breast cancer. Clin Cancer Res 2011, 17:667-677.
97. Niikura N., Liu J., Hayashi N., Mittendorf E.A., Gong Y., Palla S.L., et al. Loss of human epidermal growth factor receptor 2 (HER2) expression in metastatic sites of HER2-overexpressing primary breast tumors. J Clin Oncol 2012, 30:593-599.
98. Han H.S., Eom D.W., Kim J.H., Kim K.H., Shin H.M., An J.Y., et al. EGFR mutation status in primary lung adenocarcinomas and corresponding metastatic lesions: discordance in pleural metastases. Clin Lung Cancer 2011, 12:380-386.
99. Vakiani E., Janakiraman M., Shen R., Sinha R., Zeng Z., Shia J., et al. Comparative genomic analysis of primary versus metastatic colorectal carcinomas. J Clin Oncol 2012, 30:2956-2962.
100. Shah S.P., Morin R.D., Khattra J., Prentice L., Pugh T., Burleigh A., et al. Mutational evolution in a lobular breast tumour profiled at single nucleotide resolution. Nature 2009, 461:809-813.
101. McCormack P.L., Keam S.J. Dasatinib: a review of its use in the treatment of chronic myeloid leukaemia and Philadelphia chromosome-positive acute lymphoblastic leukaemia. Drugs 2011, 71:1771-1795.
102. Reuveni H., Flashner-Abramson E., Steiner L., Makedonski K., Song R., Shir A., et al. Therapeutic destruction of insulin receptor substrates for cancer treatment. Cancer Res 2013, 73:4383-4394.
103. Engelman J.A., Zejnullahu K., Mitsudomi T., Song Y., Hyland C., Park J.O., et al. MET amplification leads to gefitinib resistance in lung cancer by activating ERBB3 signaling. Science 2007, 316:1039-1043.
104. Bean J., Brennan C., Shih J.Y., Riely G., Viale A., Wang L., et al. MET amplification occurs with or without T790M mutations in EGFR mutant lung tumors with acquired resistance to gefitinib or erlotinib. Proc Natl Acad Sci USA 2007, 104:20932-20937.
105. McMillin D.W., Negri J.M., Mitsiades C.S. The role of tumour-stromal interactions in modifying drug response: challenges and opportunities. Nat Rev Drug Discov 2013, 12:217-228.
106. Gilbert L.A., Hemann M.T. DNA damage-mediated induction of a chemoresistant niche. Cell 2010, 143:355-366.
107. Wilson T.R., Fridlyand J., Yan Y., Penuel E., Burton L., Chan E., et al. Widespread potential for growth-factor-driven resistance to anticancer kinase inhibitors. Nature 2012, 487:505-509.
108. Straussman R., Morikawa T., Shee K., Barzily-Rokni M., Qian Z.R., Du J., et al. Tumour micro-environment elicits innate resistance to RAF inhibitors through HGF secretion. Nature 2012, 487:500-504.
109. Germano G., Frapolli R., Belgiovine C., Anselmo A., Pesce S., Liguori M., et al. Role of macrophage targeting in the antitumor activity of trabectedin. Cancer Cell 2013, 23:249-262.
110. D'Incalci M., Galmarini C.M. A review of trabectedin (ET-743): a unique mechanism of action. Mol Cancer Ther 2010, 9:2157-2163.
111. Johnston P.G., Lenz H.J., Leichman C.G., Danenberg K.D., Allegra C.J., Danenberg P.V., et al. Thymidylate synthase gene and protein expression correlate and are associated with response to 5-fluorouracil in human colorectal and gastric tumors. Cancer Res 1995, 55:1407-1412.
112. Usanova S., Piee-Staffa A., Sied U., Thomale J., Schneider A., Kaina B., et al. Cisplatin sensitivity of testis tumour cells is due to deficiency in interstrand-crosslink repair and low ERCC1-XPF expression. Mol Cancer 2010, 9:248.
113. Soverini S., De Benedittis C., Papayannidis C., Paolini S., Venturi C., Iacobucci I., et al. Drug resistance and BCR-ABL kinase domain mutations in Philadelphia chromosome-positive acute lymphoblastic leukemia from the imatinib to the second-generation tyrosine kinase inhibitor era: the main changes are in the type of mutations, but not in the frequency of mutation involvement. Cancer 2014, 120:1002-1009.
114. Camidge D.R., Bang Y.J., Kwak E.L., Iafrate A.J., Varella-Garcia M., Fox S.B., et al. Activity and safety of crizotinib in patients with ALK-positive non-small-cell lung cancer: updated results from a Phase 1 study. Lancet Oncol 2012, 13:1011-1019.
115. Berns K., Horlings H.M., Hennessy B.T., Madiredjo M., Hijmans E.M., Beelen K., et al. A functional genetic approach identifies the PI3K pathway as a major determinant of trastuzumab resistance in breast cancer. Cancer Cell 2007, 12:395-402.
116. Recupero D., Daniele L., Marchio C., Molinaro L., Castellano I., Cassoni P., et al. Spontaneous and pronase-induced HER2 truncation increases the trastuzumab binding capacity of breast cancer tissues and cell lines. J Pathol. 2013, 229:390-399.
117. Hu Y.L., DeLay M., Jahangiri A., Molinaro A.M., Rose S.D., Carbonell W.S., et al. Hypoxia-induced autophagy promotes tumor cell survival and adaptation to antiangiogenic treatment in glioblastoma. Cancer Res 2012, 72:1773-1783.